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Summary Since January 1975 a population-based screening programme for the early detection of breast
cancer has been carried out in the city of Nijmegen. During five interscreening periods of 2 years each a total
of 158 so-called interval cancers were diagnosed. Careful revision of all screening and diagnostic mammo-
grams was executed. Of all interval cancers 26% were 'missed' at the previous screening examination (due to
technical or observer error), 16% were radiographically occult at the time of diagnosis and 58% were 'true'
interval cancers. Interval cancers were regarded as 'true' when an obvious lesion was observed on the
diagnostic mammogram while no suspect signs were seen on the previous screening mammogram. The
prevalence of 'missed' cancers did not decline in the course of the screening programme. Radiographically
occult tumours were localised, mostly in Wolfe's P2/DY breast parenchyma (83%), 33% were lobular invasive
and 25% ductal non-invasive. 'True' interval cancer cases (58%) showed the same overall survival as control
breast cancer patients, diagnosed in a non-screening situation. Shortening the screening interval would reduce
interval cancer rates and probably further decrease breast cancer mortality in a screened population.
However, from the present series of interval cancers 63% would not have been prevented by an annual
screening examination. As regards women under age 50 annual screening would still leave 66% of all interval
cancers in this age group undetected. Probably more benefit will be gained by searching for new imaging
techniques to reduce numbers of 'missed' cancers and to detect lobular invasive and ductal non-invasive
cancers in dense breast parenchyma.
Within any screening programme for the early detection of
breast cancer, women are diagnosed as having so-called
interval cancer. These cancers surface among negative
screenees before the next scheduled examination would have
taken place. Of all breast cancers in a screened population
about 20-35% are diagnosed within 2 years after the last
screening examination (Verbeek, 1985; Tabar et al., 1987;
Moskowitz, 1986; de Waard et al., 1984; Lundgren, 1979).
The survival of patients with interval cancers turned out to
be just as bad as the survival of patients diagnosed outside
screening programmes (Holmberg et al., 1986; Shapiro et al.,
1982). This finding would seem to suggest that shortening
the screening interval to, say, one year might further
decrease breast cancer mortality in a population offered a
screening programme. The aim of the present study was to
search for more evidence validating such recommendations.
The issue of screening frequency is especially relevant for
women under age 50, since on the one hand no clear-cut
evidence of breast cancer mortality reduction has been
demonstrated so far in this age group, and on the other
hand relatively high interval cancer rates have been
observed (Tabar et al., 1987; Moskowitz, 1987).
Subjects and methods
All data came from the Nijmegen (150,000 inhabitants)
screening programme. This population-based project started
in January 1975. Single-view mammography was carried out
as the only screening examination every two years. In the
first screening round (1975/6) women born in the period
1910-39 (n=23,000) were invited. In the subsequent screen-
ing rounds women born before 1910 (n=7,700) were invited
too; in the fifth screening round the cohort of women born
in the period 1940-44 (n=3,900) was invited. The attendance
rate was highest for women under 50 in the first screening
round (87%) and lowest for women aged 65 or over in the
Correspondence: P.H.M. Peeters.
Received 10 July 1988; and in revised form, 24 October 1988.
sixth screening round (31%). Up to December 1986, six
screening rounds were performed. In the five interscreening
periods 158 breast cancer cases were diagnosed. Two syn-
chronic interval cancers were found. Because some women
did not return for screening two years later (at the scheduled
two-year interval), some breast cancers were diagnosed in
these non-attenders at intervals greater than two years after
the negative screening examination. These so-called 'pseudo-
interval' cancers were not included in this analysis.
All screening and diagnostic mammograms of the interval
cancer cases were carefully reviewed by the radiologist and
classified into one of the following three groups. (In five
cases the screening or diagnostic mammogram was not
available. They were all diagnosed in the early years of the
screening project.)
'Missed' cancers Forty out of all interval cancers were
classified as missed cancers, as due to either technical or
observer error.
Radiographically occult cancers Twenty-four of all interval
cancers were radiologically occult at the time of diagnosis.
'True' interval cancers Eighty-nine cancers showed a clear
lesion on the diagnostic mammogram and no suspect signs
at the preceding screening examination.
It was evaluated whether the number of 'missed' cancers
decreased during the 12-year observation period. Interval
cancers were compared with breast cancers, detected at one
of the five screening rounds, in terms of such radiological
and prognostic aspects as Wolfe classification, mammo-
graphical tumour size, age at the previous examination,
quetelet index, oestrogen receptor positivity and axillary
lymph node involvement. To evaluate the prognosis of the
'true' interval cancers the overall survival of these 89 patients
was compared with control breast cancer patients in the non-'
screened population. These control patients were recruited
among women who were diagnosed for breast cancer before
they received an invitation for a first screening examination.
Distributions of variables in two groups were compared
with standard x2 tests. Survival curves were computed with
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Table VI Alterations in theenzy*matic activity ofcytosolic GGT in the
livers of rats of different expenrmental groups
GGT activits
/nmolproduct formed min- mg- protein)
PNs NNSP Control
Group n = (5/n =5 (n=4)
A 56.90 ± 7.21'b 20.38 3.70 ' 0.78 0.10
C 12.15± 2 .90cd 5.12 1.11 0.83 0.12
E 23.25 ± 4.12b 9.31 ± 2.45c" 0.72 ± 0.09
G 37.81 ± 6.41 b 14.17 3.92 E 0.87 0.13
aEach value represents the mean ± s.e. bP<0.001. cP<0.01 and
'P< 0.02 as compared with the corresponding control. i.e. groups
B,D.F and H for groups A.C.E and G respectively. dp<0O. l.
'P<O.OI and fP< 0 05 as compared with group A.
Discussion
The results of our present investigation clearly demonstrate
that in this particular two-stage model of hepatocar-
cinogenesis in rats the supplementation of 0.5 p.p.m.
vanadium during the entire experiment, before initiation and
during promotion greatly reduced the incidence, multiplicity
and size of visible PNs with a concurrent arrest in the
number and spread of GGT-positive hepatic foci in total
liver parenchyma. In the promotional event, however, these
changes did not have any statistical significance. Our data.
thus, reveal the unique protective role of vanadium against
chemically induced liver tumorigenesis in rats and cor-
roborate our previous findings (Bishayee and Chatterjee.
1995). This time the anticarcinogenic potential of vanadium
is primarily observed on the initiation phase and only secon-
darily on the promotion stage. In this regard, it is interesting
to note that continuous long-term exposure to a low dose of
vanadium would elicit a greater protection in terms of the
magnitude of preneoplasia than exposure at either the initia-
tion or promotion phase alone.
In our experiment. the supplementation of 0.5 p.p.m.
vanadium in drinking water, especially during the entire
period of the study. resulted in fewer rats developing visible
PNs and a smaller number of nodules per nodule-bearing rat
liver than those observed in DENA control animals. Another
st'king observation of the study was the vanadium-mediated
inhibition of the appearance of PNs more than 3 mm in size
with a concurrent attenuation of nodular volume as well as
nodular volume as a percentage of liver volume. Although it
is evident that not all the hepatocyte nodules become
cancerous during the lifespan of the animals. numerous
observations support the concept that the nodules are the
precursors of hepatic cancer (Farber. 1980; Williams. 1980).
Moreover, there is a large body of observational experience
in experimental and human disease correlating the number
and size of nodular hyperplasia and hepatocarcinoma
(Farber and Cameron. 1980: Farber. 1990). In view of this.
inhibition of nodule growth and enhancement of their regres-
sion by vanadium as observed in our study may be important
for cancer prevention. especially if one considers that the
PNs are easily recognisable and have a low tendency to
regress spontaneously. Again, the food and fluid intakes and
changes in body weights among different experimental groups
were found to be statistically similar. This feature is of
paramount importance because nutritional deprivation caus-
ing body weight loss may parallel a decrease in tumour
volume (Waitzberg et al.. 1989). Thus. the observed
inhibitory effect of vanadium on nodule appearance and its
growth is unlikely to be mediated through the impairment of
nutritional status in the experimental animals.
It is generally accepted that GGT-positive foci appear to
be the first discernible evidence for the occurrence of tumour
initiation (Farber. 1980: Pitot and Sirica. 1980). Moreover.
the use of GGT-positive foci in initiation-promotion bioas-
say is predicted on the assumption that the incidence of foci
correlates with the eventual tumour yield that would have
occurred had the assav continued until tumour formation
(Farber. 1980: Pereira. 1982). In the present study. our
results clearly showed an inhibitory role of vanadium on the
number of GOT-positive preneoplastic focal lesions per cmn
of the livers of rats initiated with DENA. As GGT-positive
foci represent a transient step to malignancy (Tatematsu et
al.. 1988). the ability of vanadium to reduce the development
of GGT-positive foci suggests that this trace element can
greatly affect the initiation stages of hepatocarcinogenesis by
preventing the initiated cells from growing into preneoplastic
foci through an alteration in the efficiency at which DENA
can initiate foci appearance. The potential role of vanadium
in reducing the number of foci per cmr of liver area was also
reflected through a relatively high remodelling and low labell-
ing index. This strongly indicates that a progressive loss of
growth capacity by putative preneoplastic cells and their
differentiation into normal-appearing hepatocytes proceed to
a greater extent in the presence of vanadium.
According to the well-accepted hypothesis of Pitot et al.
(1989). the number and size of altered liver cell foci indicate
initiating and promoting activities respectively. In our study.
vanadium supplementation not only decreased the number of
GGT-positive preneoplastic foci but also caused a decrement
in the focal area with a concomitant reduction in focal area
as a percentage of liver area, though the results were statis-
tically more significant with respect to focal number. How-
ever. this strongly points out the influence of vanadium in
inhibiting or slowing the growth of altered liver cell foci. The
observed effect of vanadium on focal growth may represent a
selective toxicity to proliferating cells by virtue of the fact
that they are proliferating compared with a relatively non-
proliferating background and thereby eventually suppress the
occurrence of hepatocarcinogenesis. In this regard. it is inter-
esting to note that, although GGT-positive foci appeared in
the livers of all the vanadium-treated rats concomitant with
DENA administration (foci incidence 100%). only a few rats
exhibited PNs in their livers (nodule incidence 41.6-72.7% in
the three vanadium-supplemented groups). Since PNs arise
from enzyme-altered focal growth (Feo et al.. 1988). our
present findings could be explained in the light of the fact
that. although the precursor lesions were still present in the
livers of vanadium-exposed rats. their growth rate slowed to
such an extent that appearance of PNs was delayed beyond
the experimental end point owing to an increased latency
penod. This interpretation is supported by our histological
assessment, in which the livers of vanadium-supplemented
animals (specially in groups C and E) presented a well-
maintained liver architecture with relatively less acidophilic
hepatocyte areas than DENA controls.
The enzymatic activity of GGT has been identified as a
possible positive marker for preneoplastic hepatocytes
(Cameron et al.. 1978: Hanigan and Pitot. 1985). In the
current study its activity was measured quantitatively in
different cell populations during the induction of liver cancer
with DENA in the presence or absence of vanadium.
Although GGT activity is located inside the plasma memb-
rane, we performed our study using cytosol as it is generally
released in a soluble form by homogenisation. Elhkim et al.
(1992) also observed that at least 80% of the total GGT
activity was present in the cytosolic fraction. Further. PB is
known to be a very weak inducer of GOT alone and, in
combination with the initiating carcinogen DENA. the induc-
tion increases greatly (Shirai et al.. 1985). The exponential
increase in the activity of GGT in PNs and NNSP following
DENA injection as observed here resembled a growth pro-
cess which onrginated as a response to toxic cellular injury.
As there is evidence for a close connection between GGT
activation and carcinogenesis (Fiala and Fiala. 1973). a large
increase in this enzyme activity could be correlated with a
high nodule incidence, a high total number and a large
spread of nodules and foci in hepatic tissue. Vanadium-
mediated inhibition of GOT-positive hepatocyte foci and
PNs during rat liver carcinogenesis initiated with DENA and
promoted by PB was well reflected in the relatively low level
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Table III Reasons for missed detection on screening mammogram
Incorrect positioning 2
Technical errot-
Strange location tumour 12
rDirect signs 16
Observer error
Less specific signs 10
Direct signs: presence of a mass, malign microcalcifications, nipple
retraction, diffuse lymphoedema, skin thickening or spiculation.
Less specific signs: a vague progressive density in a specific area
or slight disturbance of the architectural pattern, or slight asym-
metry of breast tissue.
year overall actuarial survival was 72.0% (s.e. +6.1%). In
control patients, diagnosed for breast cancer before being
eligible for a screening invitation, overall survival was 60.2%
(s.e. +5.2%). Differences in survival curves approached statis-
tical significance (log rank x2 3.2, P=0.07). Control patients
were older when compared with 'true' interval cancer
patients (47% aged 65 years or older vs. 21%). Age (contin-
uous) included as an explanatory variable in a proportional
hazards model showed a hazard of 0.97 (P=0.91) for
interval cancer patients compared with control patients. This
indicated the hazard to be the same for individuals with
'true' interval cancers as for control patients. The same
results were found in proportional hazards models for
women below age 50, and for women aged 50 or older.
Epidemiological, histological and radiographical features are
displayed in Table IV. 'True' interval cancers did not differ
from breast cancers in the control group, they only showed
less axillary involvement (35.5% vs. 58.0%, P=0.005). Com-
pared with screen-detected cancers 'true' interval cancers
were larger (94% > 10mm vs. 73%, P=0.02). Diagnosis was
made on average 15.2 months after the previous screening
examination. Thirty-six per cent of 'true' interval cancers
were diagnosed within one year after the screening
examination.
Discussion
The results of breast cancer screening projects such as the
HIP-trial in the United States (Shapiro et al., 1982) the
DOM-project in Utrecht (Collette et al.. 1984), the Nijmegen
screening project (Verbeek et al., 1984). the Italian project
(Palli et al., 1986) and the Swedish trial (Tabar et al., 1985a)
show a considerable reduction of breast cancer mortality.
But even though early detection and early treatment are no
longer disputed as being beneficial, some unsolved problems
remain. One of the major problems one faces in a breast
cancer screening project is the number of interval cancers. In
the Nijmegen programme, where a screening examination
was performed every 2 years, crude interval cancer rates
remained relatively stable over the 12-year period. Other
studies showed similar interval cancer rates. (Baker, 1982;
Frisell et al., 1987; T'abar et al., 1985b). Interval cancers
occurred more frequently among women under 50 years of
age, when compared to women aged 50 or older. For
younger women the ratio between interval cancers and
screen-detected cancers was about 1: 1 while this was about
1:2.5 for women aged 50 or older.
Previous studies (Holland et al., 1982; Newsome &
McLelland, 1986; Martin et al., 1979; van Rosen et al., 1985)
showed one third of all interval cancers to be missed at a
preceding screening examination due to either technical or
observer error. In the present study 26% of interval cancers
were missed. This percentage did not decline in the course of
the programme. To some extent this may have been caused
by the entry of new cohorts of women into the screening
project. In the Nijmegen programme women born in the
period 1940-44 were not invited for a screening examination
until 1983/4. Reading mammograms of these young women
is difficult due to the high density of the breast parenchyma.
Some of the missed cancers, however, were due to non-
specific changes, such as a vague progressive density or a
slightly disturbed architectural pattern. Referral of such
lesions for further clinical evaluation probably would have
resulted in a large number of false-positive screening results.
From a total of 153 interval cancers, 16% were radio-
graphically occult at the time of diagnosis. Occult cancers
are clinically detectable before they show mammographically
suspect signs. During growth they tend to remain obscured
by dense P2/DY breast parenchyma. Occult cancers often
were of lobular invasive or ductal non-invasive histological
type. In other studies about 5-7% of breast cancer patients
were reported to have negative mammograms. Patients were
younger compared with all other breast cancer patients
(Burns et al., 1979; Cahill et al., 1981). Here the limits of
modern mammography have been reached since in dense
breast parenchyma these types of breast cancers probably
cannot be visualised (Holland et al., 1983).
Of all interval cancers 58% showed no suspect lesions on
a previous screening mammogram, while they were visible at
the time of diagnosis. They were either masked in some way
at the previous examination or were newly grown, which
implies a high growth rate. A similar percentage of 'true'
interval cancers (52%) was found in the Stockholm screening
programme (Frisell et al., 1987). Although in patients with
'true' interval cancers axillary lymph node involvement was
statistically significantly less frequent (36% vs. 58%) when
compared with control breast cancer patients, 7-year overall
survival was equal. These results are identical to those
Table IV Percentages of epidemiological, histological and radiological aspects of interval cancers (i.e. 'missed'
cancers, radiographically occult cancers and 'true' interval cancers), screen-detected cancers and cancers of control
patients (i.e. with a diagnosis of breast cancer before any screening invitation)
'Missed' Radiographically 'True' Screen-detected Control
cancers occult cancers interval cancers patients
Factor (n =40) (n =24) (n =89) (n =305) (n = 127)
Age <50 yearsa 27.5 50.0 30.3 17.7 38.6h
Quetelet index <25b 37.5 62.5 32.6 37.4 -i
Oestrogen receptor pos.C 75.7 64.3 65.8 80.0 62.5
Wolfe P2/DY 50.0 83.3 47.2 38.0 50.4
Axillary node involvementd 32.4 28.6 35.5 22.4 58.0
Tumour size <10mme 5.0 - 5.6 27.2 10.4
Histology: DCISf - 25.0 5.6 9.9 3.2
Duct invasive 74.4 41.7 66.3 75.0 81.1
Lobular invasive 12.8 33.3 16.9 6.9 9.5
Otherg 12.8 - 11.2 8.2 6.3
aAge at screening examination; bQuetelet index=kgm 2; COestrogen receptor positive >10fmolmg 1; dIn the
early years of the screening programme it was neither a national nor a local practice to remove the axillary lymph
nodes for histologic examination; eSize of the tumour on the mammogram at diagnosis; 'DCIS=duct carcinoma in
situ; =ther =tubular carcinoma, medullary carcinoma, papillary carcinoma; hAge =age at diagnosis; 'Not known for
control patients.
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reported by others (Holmberg et al., 1986; Shapiro et al.,
1982).
It is often argued that shortening the screening interval
would reduce the number of interval cancers (Tab'ar et al.,
1987; Moskowitz & Gartside, 1982). Especially the high
proportion of interval cancers occurring in women under age
50 is reported to cause the absence of a clear reduction in
mortality in women from this age-group, after participating
in a screening programme. More frequent screening will
probably not affect the number of 'missed' cancers, since the
same error rates of about 30% are found in studies with
different screening intervals (Baker, 1982; Holland et al.,
1982; Newsome & McLelland, 1986; Martin et al., 1979). In
the Nijmegen project the prevalence of 'missed' interval
cancers did not decrease during the progress of the pro-
gramme. More frequent screening will certainly not improve
the detection of radiographically occult breast cancers, it can
only influence the 'true' interval cancer group of 58%.
However, since 32 of these 89 interval cancers occurred
within one year after the previous screening examination an
annual screening examination would still leave 40 ('missed'
cancers) plus 24 (radiographically occult cancers) plus 32
('true' interval cancers occurring within one year) undetected.
So from the present series of 153 interval cancers, 96 (63%)
would not have been prevented by more frequent screening.
As regards women under age 50, from a total of 51 interval
cancers (50, one missing) 11 were 'missed' at the previous
screening examination, 12 were radiographically occult and
10 of the 'true' interval cancers occurred within one year
after the preceding screening examination. For this age-
group shortening the screening interval from 2 years to 1
year would prevent 34% of interval cancers. This age-group
would probably benefit more from the development of new
imaging techniques to detect specific lobular invasive and
ductal non-invasive cancers in dense breast tissue.
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